相关实验视频

Updated: Jul 5, 2025

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

现实世界阿普雷米拉斯的使用在生物素质素的牛皮关节炎患者中. 来自西班牙临床实践的数据

Jordi Gratacós-Masmitja¹, Emma Beltrán Catalán², José Luis Álvarez Vega³

¹Rheumatology Service, University Hospital Parc Taulí (I3PT), Medicine Department UAB, Barcelona, Spain.

Reumatologia clinica

|January 17, 2024

概括

三分之二的牛皮关节炎患者在12个月内继续接受premilast治疗,在现实西班牙临床实践中显示疾病活性,关节健康和生活质量有显著改善.

科学领域:

类风湿病学类风湿病学
临床药理学临床药理学
现实世界证据研究实证研究

背景情况:

阿普雷米拉斯特是治疗牛皮和牛皮性关节炎 (PsA) 的批准药物.
在常规的临床环境中,关于apremilast有效性的现实数据有限.

研究的目的:

评估阿普雷米拉斯特在西班牙生物先验的PsA患者中的实际有效性和持久性.
为了评估12个月的疾病活动,关节状况和患者报告结果的变化.

主要方法:

一项观察性研究涉及59名未经生物治疗的成年PsA患者,他们在21个西班牙中心启动了apremilast.
在启动后的6个月和12个月收集的数据,重点关注apremilast持久性.
二次结局包括PSA的疾病活动 (DAPSA),关节侵蚀,肠炎,牙炎和PsA疾病影响 (PsAID) 问卷对生活质量.

主要成果:

在6个月后,阿普雷米拉斯的持久性为75%,在12个月后为67%.
在DAPSA得分中观察到显著改善,缓解/低疾病活性在12个月内从33%增加到78%.
牙炎 (35.6%至11.6%) 和肠炎 (28.8%至2.4%) 的发病率降低,侵蚀没有放射性进展,超过三分之二的患者达到可接受的症状状态 (PsAID-9 <4).

结论:

在西班牙的临床实践中,阿普雷米拉斯特在PsA患者中表现出持续的有效性.
观察到的好处包括维持治疗持续性,改善关节健康,无放射性进展,以及患者报告的改善生活质量.

关键词:

在4月的最后一天.牛皮形关节炎 (psoriásica) 是一种疾病.生物上的天真.生物学上是 naive 的.一个观察性研究.证据是真实的,真实的.观察性研究是一种观察性研究.持久性牛皮关节炎持续性持续性持续性现实世界的证据.

更多相关视频

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Antiasthma Drugs: Leukotriene Modifiers

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...